YBL-001 is a Delta-like 1 homolog(DLK1)-targeting antibody-drug conjugate (DLK1-ADC) produced by conjugating an apoptotic payload to an antibody capable of being internalized and entering cells while binding specifically to DLK1 expressed in cancer cells. DLK1 has been observed to be overexpressed in patients with liver cancer, colorectal cancer, breast cancer, small cell lung cancer, and pancreatic islet cell tumors, and it is reported to be associated with cancer recurrence and metastasis as a cancer stem cell biomarker. YBL-001 can selectively kill DLK1-expressing cancer cells by specifically binding to DLK1, entering the cells, and releasing the conjugated toxic payload in the lysosome.

YBL-015 is an antibody-drug conjugate (ADC) produced by conjugating a cytotoxic payload to a B7-H3-specific antibody. B7-H3 is a promising and novel target of the immune checkpoint family. While the expression of B7-H3 in normal cells is very limited, it is highly expressed in patients with solid tumors in the breast, lung, pancreas, prostate, kidney, colon, skin or brain. YBL-015 utilizes a highly specific antibody for B7-H3 and can selectively kill cancer cells where B7-H3 is highly expressed.